Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Philip

Showing results (451-460 of 521) with videos related to

Pageof 53
Sort By:
NPJ Precision Oncology|June 15, 2026
Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligenceSebastian Cole, Paul Campitelli, Brian Grieb, et al.
World Journal of Gastroenterology|March 6, 2015
Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumorsJonathan R Strosberg, George A Fisher, Al B Benson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatmentPhilip A Philip, Margaret Mooney, Deborah Jaffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2016
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313Ramesh K Ramanathan, Shannon L McDonough, Philip A Philip, et al.
Complementary Therapies in Clinical Practice|April 9, 2008
Antibacterial activity of honey against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)Yasunori Maeda, Anne Loughrey, J A Philip Earle, et al.
Oncogene|May 26, 2022
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targetsAlberto Puccini, Kelsey Poorman, Fabio Catalano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 2, 2020
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205Philip A Philip, Jacqueline Benedetti, Christopher L Corless, et al.
The American Journal of Gastroenterology|November 11, 2018
High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic CancerShounak Majumder, Nissy A Philip, Sajan Jiv Singh Nagpal, et al.
Pageof 53

Showing results (451-460 of 521) with videos related to

Sort By:
Pageof 53
NPJ Precision Oncology|June 15, 2026
Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligenceSebastian Cole, Paul Campitelli, Brian Grieb, et al.
World Journal of Gastroenterology|March 6, 2015
Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumorsJonathan R Strosberg, George A Fisher, Al B Benson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatmentPhilip A Philip, Margaret Mooney, Deborah Jaffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2016
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313Ramesh K Ramanathan, Shannon L McDonough, Philip A Philip, et al.
Complementary Therapies in Clinical Practice|April 9, 2008
Antibacterial activity of honey against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)Yasunori Maeda, Anne Loughrey, J A Philip Earle, et al.
Oncogene|May 26, 2022
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targetsAlberto Puccini, Kelsey Poorman, Fabio Catalano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 2, 2020
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205Philip A Philip, Jacqueline Benedetti, Christopher L Corless, et al.
The American Journal of Gastroenterology|November 11, 2018
High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic CancerShounak Majumder, Nissy A Philip, Sajan Jiv Singh Nagpal, et al.
Pageof 53